A Phase 1 Mass Balance Study of Varegacestat

ClinicalTrials.gov ID: NCT06845852

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06845852. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]Varegacestat Following a Single Oral Dose in Healthy Adult Male Participants

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This clinical study is designed to study the mass balance of a single dose of varegacestat in healthy male participants.

Study identification

NCT ID: NCT06845852
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Immunome, Inc.; Industry
Enrollment: 6 participants

Conditions and interventions

Conditions

Healthy Volunteer

Interventions

varegacestat Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 55 Years
Sex: Male
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 25, 2025 (Actual)
Primary completion: Mar 11, 2025 (Actual)
Completion: Mar 26, 2025 (Actual)
Last update posted: Sep 26, 2025

2025

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Frontage Laboratories, Inc.	Secaucus	New Jersey	07094	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06845852, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 26, 2025 · Synced Nov 14, 2026